Key result
Compound G07 demonstrated significant anti-influenza virus A/WSN/33 (H1N1) activity with an EC50 of 11.38 µM and IC50 of 0.23 µM, and interacted well with ribonucleoprotein.
Population
Influenza virus strains A/WSN/33 (H1N1), A/PR/8 (H1N1), A/HK/68 (H3N2), and influenza B virus
Comparison
4-[(quinolin-4-yl)amino]benzamide derivatives evaluated for anti-influenza activity
Design
In vitro and in silico preclinical study
Authors
Loading...
Does not support clinical use; leaves open further preclinical development of novel antivirals.
Compound G07, a novel 4-[(quinolin-4-yl)amino]benzamide derivative, demonstrates significant in vitro anti-influenza activity, potentially by targeting the PA-PB1 subunit of RNA polymerase.
Zhang et al. (2022) studied Influenza virus infection. 4-[(quinolin-4-yl)amino]benzamide derivatives (Compound G07) was evaluated on Anti-influenza virus A/WSN/33 (H1N1) activity. Compound G07 demonstrated significant anti-influenza virus A/WSN/33 (H1N1) activity with an EC50 of 11.38 µM and IC50 of 0.23 µM, and interacted well with ribonucleoprotein.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: